Assessing Daily-activity-level for Decisions on Bisphosphonate Prescription (ADD-BP) Study: Exploring Physical Activity as a Risk Factor for Bisphosphonate-Induced Atypical Femoral Fractures
- Conditions
- Atypical Femoral FractureAtypical Femoral Fracture, Atypical Fracture, Bisphosphonate, OsteoporosisD005264
- Registration Number
- JPRN-jRCT1020230053
- Lead Sponsor
- Yokota Takeru
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 140
Prior to December 2023, the study targets inpatients with a history of bisphosphonate (BP) use in the Fukushima Prefectural Medical University Hospital, Ohara General Hospital, Fukushima Red Cross Hospital, Nanto-Tohoku Fukushima General Hospital, and the Public Fujita General Hospital, all located in the northern region of Fukushima Prefecture.
*Patients with a history of the use of alendronate, risedronate, minodronate, ibandronate, etidronate, and zoledronic acid are considered to have a history of BP use.
The study population consists of patients with atypical femoral fractures (AFF). The control group comprises inpatients without AFF, and the same number of samples will be randomly selected as in the case group.
Patients with a history of BP use among inpatients will be listed and assigned numbers, and a random selection will be made. The number of patients sampled will be adjusted based on the size of each facility's patient population (proportional probability sampling).
Patients treated with zoledronic acid for hypercalcemia due to malignant tumors, bone lesions caused by multiple myeloma, and bone lesions resulting from bone metastasis of solid cancers.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Performing a multiple logistic regression analysis to assess the odds ratios for the occurrence of atypical femoral fractures (AFF) in relation to pre-injury activities of daily living (ADL) and seven confounding factors.
- Secondary Outcome Measures
Name Time Method